Key facts
- This page summarizes Mark Alden Tibbles's Form 3 filing for Imricor Medical Systems, Inc..
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 18 May 2026, 17:21.
Mark Alden Tibbles - 18 May 2026 Form 3 Insider Report for Imricor Medical Systems, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 18 May 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Mark Alden Tibbles
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Mark Alden Tibbles filed Form 3 for Imricor Medical Systems, Inc. on 18 May 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002132267
Primary reporting owner
Tibbles Mark Alden
- Relationship
- Director
- Address
- C/O IMRICOR MEDICAL SYSTEMS, INC., 400 GATEWAY BLVD, BURNSVILLE
- Signature
- /s/ Mark Alden Tibbles
- Signature date
- 18 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
No ticker
holding
Class A Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,062,439
- Date
- 18 May 2026
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No ticker
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 May 2026
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 254,000
- Exercise price
- $0.5200
- Footnotes
- F3
No ticker
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 May 2026
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 60,900
- Exercise price
- $0.5200
- Footnotes
- F4
No ticker
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 May 2026
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 100,000
- Exercise price
- $0.9800
- Footnotes
- F5
No ticker
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 May 2026
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 71,010
- Exercise price
- $0.8900
- Footnotes
- F6
No ticker
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 May 2026
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 40,896
- Exercise price
- $1.57
- Footnotes
- F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
The amount of securities beneficially owned in column 2 includes 5,473,504 shares of the issuer's Class A Common Stock underlying the same number of CHESS Depositary Interests ("CDIs"). The CDIs are traded on the Australian Securities Exchange (the "ASX") and are held by CHESS Depositary Nominees Pty Limited, a subsidiary of ASX Limited, the company that operates the ASX.
Footnote F2
The amount of securities beneficially owned in column 2 includes 163,307 restricted stock awards ("RSAs") granted under the issuer's 2019 Equity Incentive Plan. Each RSA represents one share of the issuer's Class A Common Stock subject to vesting conditions. The reporting person holds: (i) 44,943 RSAs remaining unvested from a May 12, 2023 grant, which RSAs will vest on May 12, 2027; (ii) 53,778 RSAs remaining unvested from a May 15, 2024 grant, which RSAs will vest 50% on each of May 15, 2027 and May 15, 2028; (iii) 30,960 RSAs remaining unvested from a May 14, 2025 grant, which RSAs will vest one-third on each of May 14, 2027, May 14, 2028, and May 14, 2029; and (iv) 33,626 RSAs granted on May 8, 2026, which RSAs will vest 25% on each of May 8, 2027, May 8, 2028, May 8, 2029, and May 8, 2030, subject in each case to the reporting person's continued service through each such vesting date.
Footnote F3
This option was granted on March 15, 2019, and vested in multiple installments over approximately two years from the grant date. This option is 100% vested.
Footnote F4
This option was granted on March 15, 2019, and vested in multiple installments over approximately three years from the grant date. This option is 100% vested.
Footnote F5
This option was granted on August 30, 2019, and vested in multiple installments over approximately four years from the grant date. This option is 100% vested.
Footnote F6
This option was granted on May 13, 2020, and vested in multiple installments over approximately four years from the grant date. This option is 100% vested.
Footnote F7
This option was granted on May 7, 2021, and vested in multiple installments over approximately four years from the grant date. This option is 100% vested.